Raghad Al-Omari et al.
interaction with other drugs is taken under considera-
tion, may result a proper therapeutic outcome for ergot.
REFERENCES
Adam G, Kurt T, Çınar C, Sarıyıldırım A, Resorlu M, Uysal F,
Yener AU, Ozcan S. (2014). Ergotamine-induced vasospastic
ischemia mimicking arterial embolism. Ulus Travma Acil Cer-
rahi Derg. 20(4): 291-294.
Ahmad A, Upadhyay A, Ahmad M, Pieters L. (2013). Antioxidant,
antliglycation and antimicrobial activities of Ziziphus oxyphylla
and Cedrela serrata Extracts. Eur J med plants. 3(4): 520-529.
Ahmad R, Ahmad M, Jahan N, Mehjabeen. (2014). Phyto-
chemical screening and anti-oxidant activity of the two plants
Ziziphus oxyphylla Edgew and Cedrela Serrata Royle. Pak J
Pharm Sci. 27(5):1477-82.
Ahmad R, Naqvi AA, Ahmad N, Baraka M, Mastour M, Al
Sharedah S, Al Ghamdi S, Al Rabae G, Al Ghamdi MS. (2017).
Awareness, perception, attitude, and knowledge regarding
complementary and alternative medicines (cams) among the
pharmacy and medical students of a public university in Saudi
Arabia. Arch Pharm Prac. 8(2):51-63.
Baldwin ZK and Ceraldi CC. (2003). Ergotism associated with
HIV antiviral protease inhibitor therapy. Journal of Vascular
surgery. 37(3): 676-678.
Bangh SA, Hughes KA, Roberts DJ, Kovarik SM. (2005). Neo-
natal Ergot Poisoning: A Persistent Iatrogenic Illness. Ameri-
can Journal of Perinatology. 22(5): 239-243.
Belser-Ehrlich S, Harper A, Hussey J, Hallock R. (2013). Human
and cattle ergotism since 1900: symptoms, outbreaks, and reg-
ulations. Toxicol Ind Health. 29(4): 307-16.
Cagatay A, Guler O, Guven K. (2009). Ergotism Caused by Con-
current Use of Ritonavir and Ergot Alkaloids: A Case. Acta
chirurgica Belgica. 109(5): 639-640.
Curry JC and Pepine JR. (1977). Effects of Ergonovine in
Patients. Circulation journal. 56(5): 803-809.
Demir S, Akın S, Tercan F, Arıbog˘ an A, Og˘uzkurt L. (2010).
Ergotamine-induced lower extremity arterial vasospasm pre-
senting. Interventional radiology, Turkish Society of Radiol-
ogy. 16(2): 165-167.
Dhlof C, Maassen A, Brink VD. (2012). Dihydroergotamine,
Ergotamine, Methysergde, and sumatriptn-Basic science in
Relation to Migraine treatment. The journal of head and face
pain banner. 52(4). 707-714.
Eadie MJ. (2003). Convulsive ergotism: epidemics of the sero-
tonin syndrome?. The lancet neurology. 2(7): 429-434.
Eduardo J, Ayarragaray F, Panno M. (2016). Ergotism and Ret-
roviral Therapies: An Association not so Unusual. JSM Foot
And Ankle. 1(3): 1-2.
Floss GH. (1976). Biosynthesis of ergot alkaloids and related
compounds. Tetrahedran. 32.873- 912.
Fröhlich G, Kaplan G, Amann-Vesti B. (2010). Holy re in an
HIV-positive man: a case of 21st-century ergotism. CMAJ.
182(4): 378-380.
Gaye-Saavedra GA, et al., (2016). Transient ischemic attack
caused by cerebral ergotism. Arquivos de Neuro-Psiquiatria.
1603(1): 114-114.
Gerhards N, Neubauer L, Tudzynski P, Shu-Ming Li. (2014).
Biosynthetic Pathways of Ergot Alkaloids. Toxins. 6(12), 3281-
3295.
Ghali R, Léan JD, Douville Y, Noël HP. (1993). Raymond Labbé.
Erythromycin-associated ergotamine. Annals of Vascular sur-
gery. 7(3): 291-296.
Lara-Castillo MC, Cornet-Masana JM, Etxabe A et al., (2016).
Repositioning of bromocriptine for treatment of acute myeloid
leukemia. Journal of Translational Medicine. 14(1): 1-11.
Lee MR. (2009). The history of ergot of rye (Claviceps pur-
purea). Journal of Royal College of Physicians of Edinburgh.
39(2). 79-84.
Liabsuetrakul T, Choobun T, Peeyananjarassri K, Islam QM.
(2007). Prophylactic use of ergot alkaloids in the third stage of
labour. Cochrane Database Syst Rev. 18;(2).
Majid P, Ghasem A, Seyed HH, Abdolkhalegh D. (2015). New
Perspective Therapy of Breast Cancer Based on Selective Dopa-
mine Receptor D2 Agonist and Antagonist Effects on MCF-7
Cell Line. Bentham Science Publishers. 10(2): 214-223.
Marcelo E, Stewart JB, Tepper. (2003). Ergotamine and Dihy-
droergotamine. The New England Center for Headache Stan-
ford USA. 7(1): 55-62.
Mulac D, Humpf HU. (2011). Cytotoxicity and accumulation of
ergot alkaloids in human primary cells. Toxicology. 11;282(3):
112-21.
Mulac D, Lepski S, Ebert F, Schwerdtle T, Humpf HU. (2013).
Cytotoxicity and uorescence visualization of ergot alkaloids
in human cell lines. J Agric Food Chem. 16;61(2): 462-71.
Mulac D, Lepski S, Ebert F, Schwerdtle T, Humpf HU. (2013).
Cytotoxicity and Fluorescence Visualization of Ergot Alkaloids
in Human Cell Lines. Journal of agricultural and food chemis-
try. 61(2). 462-471.
Musikatavorn K and Suteparak S. (2009). Ergotism unrespon-
sive to multiple therapeutic modulities, including sodium
nitroprussside resulting in limb loss. Clinical toxicology. 46(2):
157-158.
Panaccione DG, Ryan KL, Schardl CL, Florea S. (2012) Analysis
and modi cation of ergot alkaloid pro les in fungi. Methods
in Enzymology, 515: 267-290.
Schardl CL. (2015). Introduction to the Toxins Special Issue on
Ergot Alkaloids. Toxins. 7(10). 4232–4237.
Shimony A, Romem A, Horowitz S, Boehm R, Horowitz J.
(2006). Acute coronary syndrome associated with myocardial
bridging due to ergotamine treatment for migraine. Interna-
tional journal of cardiology. 113(1): E7-E8.
Sullivan R, Nelsen J, Duggineni S, Holland M. (2012). Man-
agement of methylergonovine induced respiratory. Informa
healthcare Clinical Toxicology. 51(1): 47-49.
Tseng CW et al., (2010). Acute paresthesia in a patient with
migraine. Journal of Clinical Neuroscience. 1328(1): 20-20.
362 A COMPREHENSIVE REVIEW OF ERGOT BIOSCIENCE BIOTECHNOLOGY RESEARCH COMMUNICATIONS